The relationship between serum testosterone and bone mineral density in Japanese men and the effects zoledronic acid in prostate cancer patients with low serum testosterone
Although hormone therapy is definitely beneficial for patients with prostate cancer, a decrease in bone mineral density and an increased risk of fracture have been noted as adverse events. Improving bone metabolism in these patients is especially important in an aging society. We herein report th...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MRE Press
2024-01-01
|
| Series: | Journal of Men's Health |
| Subjects: | |
| Online Access: | https://oss.jomh.org/files/article/20230928-100/pdf/JOMH2023101602.pdf |
| Summary: | Although hormone therapy is definitely beneficial for patients with prostate
cancer, a decrease in bone mineral density and an increased risk of fracture have
been noted as adverse events. Improving bone metabolism in these patients is
especially important in an aging society. We herein report the results of two
studies: the first examined the effect of low serum testosterone levels on bone
mineral density in a large number of Japanese men; the second study investigated
the effect of a 12-month formulation of zoledronic acid injection for multiple
years in prostate cancer patients with castration levels of serum testosterone
due to androgen deprivation therapy. The first study included 1112
patients with late-onset hypogonadism. A multiple regression analysis that
included factors that were significant in the simple regression analysis showed
that only age (p < 0.001) and testosterone (p = 0.013) were
significantly associated with bone mineral density. A significant relationship
between serum testosterone and bone mineral density was also found in an
age-adjusted regression analysis (p = 0.008) and a trend analysis
(Ptrend = 0.001). The second study included 12 prostate cancer patients with
castration levels of serum testosterone due to androgen deprivation therapy, and
who had received a 12-month formulation of zoledronic acid injection for multiple
years. A trend analysis clearly showed that bone mineral density tended to
increase year by year during the 4-year observation period (Ptrend < 0.001). In
addition, we found no treatment-related adverse events in patients who received
long-acting zoledronic acid. Thus, we conclude that men with lower serum
testosterone levels are likely to have reduced bone mineral density and wish to
emphasize that bone mineral density can be increased in prostate cancer patients
by the continuous administration of long-acting zoledronic acid at 12-month
intervals, even when their serum testosterone levels are below castration level. |
|---|---|
| ISSN: | 1875-6867 1875-6859 |